# A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

> **NCT05587049** · — · RECRUITING · sponsor: **AbbVie** · enrollment: 70 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05587049
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05587049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05587049, "A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05587049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*